GLS and hepatocellular carcinoma: Therapeutic interventions targeting GLS1, such as canagliflozin, exhibit the potential to impede glutamine metabolism, induce apoptosis in malignant cells, and sensitize HCC towards cisplatin(CPT) (33, 34).